Spots Global Cancer Trial Database for arq 501 in combination with gemcitabine
Every month we try and update this database with for arq 501 in combination with gemcitabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | NCT00102700 | Pancreatic Canc... Adenocarcinoma | ARQ 501 in comb... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |